191 related articles for article (PubMed ID: 12222548)
1. Valganciclovir: A new oral alternative for cytomegalovirus retinitis in human immunodeficiency virus-seropositive individuals.
Segarra-Newnham M; Salazar MI
Pharmacotherapy; 2002 Sep; 22(9):1124-8. PubMed ID: 12222548
[TBL] [Abstract][Full Text] [Related]
2. Valganciclovir: an advance in cytomegalovirus therapeutics.
Cocohoba JM; McNicholl IR
Ann Pharmacother; 2002 Jun; 36(6):1075-9. PubMed ID: 12022911
[TBL] [Abstract][Full Text] [Related]
3. Valganciclovir.
Curran M; Noble S
Drugs; 2001; 61(8):1145-50 ; discussion 1151-2. PubMed ID: 11465875
[TBL] [Abstract][Full Text] [Related]
4. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.
Martin DF; Sierra-Madero J; Walmsley S; Wolitz RA; Macey K; Georgiou P; Robinson CA; Stempien MJ;
N Engl J Med; 2002 Apr; 346(15):1119-26. PubMed ID: 11948271
[TBL] [Abstract][Full Text] [Related]
5. Valganciclovir: new preparation. CMV retinitis: a simpler, oral treatment.
Prescrire Int; 2003 Aug; 12(66):133-5. PubMed ID: 12906021
[TBL] [Abstract][Full Text] [Related]
6. Valganciclovir hydrochloride (Valcyte): a new antiviral agent.
Weiskittel P
Nephrol Nurs J; 2003 Feb; 30(1):93-5. PubMed ID: 12674959
[No Abstract] [Full Text] [Related]
7. Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host.
Freeman RB
Expert Opin Pharmacother; 2004 Sep; 5(9):2007-16. PubMed ID: 15330737
[TBL] [Abstract][Full Text] [Related]
8. A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis.
Lalezari J; Lindley J; Walmsley S; Kuppermann B; Fisher M; Friedberg D; Lalonde R; Matheron S; Nieto L; Torriani FJ; Van Syoc R; Sutton MA; Buhles W; Stempien MJ;
J Acquir Immune Defic Syndr; 2002 Aug; 30(4):392-400. PubMed ID: 12138345
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.
Brown F; Banken L; Saywell K; Arum I
Clin Pharmacokinet; 1999 Aug; 37(2):167-76. PubMed ID: 10496303
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic developments in cytomegalovirus retinitis.
Hoffman VF; Skiest DJ
Expert Opin Investig Drugs; 2000 Feb; 9(2):207-20. PubMed ID: 11060672
[TBL] [Abstract][Full Text] [Related]
11. Valganciclovir hydrochloride.
Am J Health Syst Pharm; 2001 Dec; 58(23):2246-7. PubMed ID: 11763801
[No Abstract] [Full Text] [Related]
12. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts.
Razonable RR; Paya CV
Expert Rev Anti Infect Ther; 2004 Feb; 2(1):27-41. PubMed ID: 15482169
[TBL] [Abstract][Full Text] [Related]
13. Incremental cost-effectiveness analysis of intravenous ganciclovir versus oral ganciclovir in the maintenance treatment of newly diagnosed cytomegalovirus retinitis in patients with AIDS.
Rachlis A; Smaill F; Walker V; Hotchkies L; Jones A
Pharmacoeconomics; 1999 Jul; 16(1):71-84. PubMed ID: 10539123
[TBL] [Abstract][Full Text] [Related]
14. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis.
Boivin G; Gilbert C; Gaudreau A; Greenfield I; Sudlow R; Roberts NA
J Infect Dis; 2001 Dec; 184(12):1598-602. PubMed ID: 11740736
[TBL] [Abstract][Full Text] [Related]
15. Treating HIV-associated cytomegalovirus retinitis with oral valganciclovir and intra-ocular ganciclovir by primary HIV clinicians in southern Myanmar: a retrospective analysis of routinely collected data.
Murray J; Hilbig A; Soe TT; Ei WLSS; Soe KP; Ciglenecki I
BMC Infect Dis; 2020 Nov; 20(1):842. PubMed ID: 33187478
[TBL] [Abstract][Full Text] [Related]
16. Oral ganciclovir for cytomegalovirus retinitis in patients with AIDS: results of two randomized studies.
Squires KE
AIDS; 1996 Dec; 10 Suppl 4():S13-8. PubMed ID: 9110065
[TBL] [Abstract][Full Text] [Related]
17. Treatment of cytomegalovirus retinitis with oral valganciclovir in an acquired immunodeficiency syndrome patient unresponsive to combination antiretroviral therapy.
Lee CH; Bright DC; Ferrucci S
Optometry; 2006 Apr; 77(4):167-76. PubMed ID: 16567278
[TBL] [Abstract][Full Text] [Related]
18. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
Caldés A; Gil-Vernet S; Armendariz Y; Colom H; Pou L; Niubó J; Lladó L; Torras J; Manito N; Rufí G; Grinyó JM
Transpl Infect Dis; 2010 Jun; 12(3):204-12. PubMed ID: 20002612
[TBL] [Abstract][Full Text] [Related]
19. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation.
Montesinos P; Sanz J; Cantero S; Lorenzo I; Martín G; Saavedra S; Palau J; Romero M; Montava A; Senent L; Martínez J; Jarque I; Salavert M; Córdoba J; Gómez L; Weiss S; Moscardó F; de la Rubia J; Larrea L; Sanz MA; Sanz GF
Biol Blood Marrow Transplant; 2009 Jun; 15(6):730-40. PubMed ID: 19450758
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal ganciclovir maintenance injection for cytomegalovirus retinitis: efficacy of a low-volume, intermediate-dose regimen.
Teoh SC; Ou X; Lim TH
Ophthalmology; 2012 Mar; 119(3):588-95. PubMed ID: 22137552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
